Ireland
--:--IST
Starting soon Not applicable

Bristol Stool Scale-Based Care Pathway for Enteral Nutrition-Associated Diarrhea in Critically Ill Patients

NCT07683364 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2026-06-15
Last updated
2026-07-06

Condition(s) studied

Critical IllnessDiarrhea

Investigational drug(s) / intervention(s)

BSFS-Based Diarrhea Care PathwayRoutine ICU Enteral Nutrition Care

BSFS-Based Diarrhea Care Pathway: Standardized nursing pathway: stool assessment every 4 h using the Bristol Stool Form Scale, with graded interventions (monitoring frequency, infusion-rate adjustment, formula change, probiotics, perianal skin protection, stepwise feeding resumption) triggered by stool type 5/6/7. Applied to the Care Pathway Group.

Routine ICU Enteral Nutrition Care: Standard ICU nursing for enteral nutrition without systematic BSFS assessment.

Study summary

Enteral nutrition-associated diarrhea (ENAD) is one of the most common gastrointestinal complications in critically ill patients receiving enteral nutrition, with a reported incidence of 22.3%-63.1%. Current management lacks a standardized nursing process and relies on individual nurse experience. This study constructs a standardized nursing care pathway driven by the Bristol Stool Form Scale (BSFS) and evaluates, in a prospective randomized controlled design, whether it reduces the severity of ENAD compared with routine ICU care. Eligible mechanically fed ICU patients are randomized 1:1 to the care-pathway group or the routine-care group, observed for 7 days (D1-D7) with a follow-up assessment on D14. The primary endpoint is the Hart diarrhea score over the observation period.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * ICU critically ill patient (APACHE II score ≥15). * Receiving enteral nutrition via nasogastric or nasojejunal tube. * No diarrhea in the 24 hours before enrollment (stool frequency \<3/day or BSFS type \<5). * Written informed consent provided by the patient or legal representative. Exclusion Criteria: * Known allergy to components of the enteral nutrition formula used. * Organic bowel disease such as inflammatory bowel disease or short bowel syndrome. * Pre-existing diarrhea at enrollment (≥3 stools/24 h and BSFS type ≥5). * Severe hepatic insufficiency. * Clostridioides difficile infection or other stool-culture-confirmed infectious diarrhea. * Pregnant or lactating women. * Currently participating in another clinical study. * Any other condition deemed unsuitable by the investigator.

Primary outcome measure(s)

  • Severity of enteral nutrition-associated diarrhea — Daily across the observation period (Day 1 to Day 7)
    Diarrhea severity rated by the Hart scoring method; each stool over 24 h is scored and summed for a daily total; total ≥12 indicates diarrhea. Rated by independent blinded assessors.
  • Incidence of ENAD — Day 1 to Day 7
    Proportion meeting the diarrhea definition (Hart ≥12, or ≥3 stools/24 h with BSFS ≥5, or stool ≥500 g/24 h).

Trial sites (1)

FacilityCityRegionStatus
Department of Critical Care Medicine, Tangdu Hospital, Fourth Military Medical University Xi'an Shaanxi
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07683364 on ClinicalTrials.gov ↗ ← All trials in China